from the below we see u are recklessly accusing th
Post# of 9122
(Total Views: 459)
Posted On: 07/14/2018 5:42:28 PM
from the below we see u are recklessly accusing the ceo
last NNLX financials has shown over 400% yoy growth in income and CA's exceeded CL's-rare in pinks
from an April update we see another confirmation in a long line of confirmations that income continues to grow: "domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion"
You are falsely accusing the ceo w a reckless disregard for the truth- the 1964 usa Supreme Ct defamation standard for allegations re public figures/celebrities-and the ceo of a small penny is not a celebrity so the standard negligence standard would be far closer to the standard re the ceo. I've posted this several times.
[iu]n your personal vendetta against the CEO,the kind which often come from previous employees, you know the things u have said are false bc I've posted the ff info before and it is readily available to everybody on the NNLX website and otc markets
[/u]
last NNLX financials CEO had loaned NNLX $100,958. In fact, back then bashers were making fun of him not being able to finish his house -not mentioning it was bc he had loaned NNLX over 100k, bc bashers are not interested in the truth.
NNLX current assets(CA) 122k current liabilites (CL) 115k of which 100k was loan from CEO
most pinks dont have products or revenues. For those who do, many have a highly negative current ratio,meaning current liabilities exceed current assets. Many pinks are defacto bankrupt. NNLX has avoided that by very carefully watching and cutting costs,avoiding toxic financing,while increasing revenues.
Even Walmart has had CL's exceeding CA's last 2 years w 59.664 CA and 78.521B CL's! so WMT's CL's exceed CA's by 18.857B!!! yet nobody is crying Walmart is falling
Financial Matters
As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market.
The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors.
The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised.
To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors
--- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.
In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.
Oct 26, 2015:
NanoLogix BioTechnology announces:
1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. The research was on three bacteria --- Neisseria Gonorrhea, Group B Streptococcus, and Enterococcus and was focused upon their rapid detection, identification, and the determination of their antibiotic resistance and sensitivity to multiple antibiotics. The results, in a few words, are: very positive, huge, phenomenal, great, unprecedented , to say the least. The N-Assay appears to work rapidly to identify any bacteria for which there exists an antibody.
2) With the delivery today of 100,000+ petri plates, NanoLogix Biotechnology has moved exclusively to using petri plates from Gosselin (A Corning company). The Gosselin products, previously purchased by the Company in 50,000+ plate lots, have enabled the company to increase economy of scale by 20% over other manufacturers' products
3) NanoLogix has reached an agreement with a multi-billion dollar medical technology company to customize the N-Assay diagnostic technology for their requirements. The work is being financed by the client and upon successful completion is projected to result in sales of multiple thousands of N-Assay kits.
4) The largest single-customer, single-day sale in the history of the company has just occurred , for an amount in excess of $30,000.00 The order was for agar-filled petri plates.
April 19,2018
Update On Petri FlatPack International Patent Status
Pursuant to NanoLogix' International Patent Offering
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
Posted On: 04/12/2018 12:44:04 PM
Posted By: Kachingpdx1
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
International Patent Offering
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
?The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Feb 24, 2014:
NanoLogix Petri technology sets new record for shelf life, NanoLogix has been informed by an independent third-party* testing facility that the ongoing room temperature shelf life test results from 7 Feb 2014 have successfully reached the 19-month point with NanoLogix Tryptic Soy Agar (TSA) plates packed in FlatPacks in July 2012 performing as well as one-week old competitor's plates.
In this ongoing study, NanoLogix TSA petri plate shelf life has reached nearly 10 times the competition's room temperature shelf life of slightly over 2 months. Prior to this study, the standard for storage of TSA petri plates was for cold storage only, for a period of 3-1/2 months. In internal company cold storage tests, NanoLogix plates are approaching the three-year point with no loss of viability. The importance of these results cannot be overstated --- growth media and petri plates have historically been mixed and filled (or poured) in locations that are limited to the states, regions, or countries in which the users are located due to the perishable nature of the products. The long shelf life of our products, and resistance to breakage in shipment of NanoLogix products are producing a paradigm shift on the part of those who are the product end users to one where they can now take delivery of our products thousands of miles distant from the production location and be assured that they have a product that significantly outlasts others made onsite or locally. A number of our petri-based products can be stored at room temperature for months or more, a feature that is unique to NanoLogix products and one that reduces energy requirements significantly on projects both large and small, with no need for cold storage equipment for our TSA (19+ months), Nematode Growth Media (12+ months), Chocolate Agar (10+ months) petri plates.
*NanoLogix is prohibited by contract from revealing the identity of the main third-party entity with which they work. more >>>
last NNLX financials has shown over 400% yoy growth in income and CA's exceeded CL's-rare in pinks
from an April update we see another confirmation in a long line of confirmations that income continues to grow: "domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion"
You are falsely accusing the ceo w a reckless disregard for the truth- the 1964 usa Supreme Ct defamation standard for allegations re public figures/celebrities-and the ceo of a small penny is not a celebrity so the standard negligence standard would be far closer to the standard re the ceo. I've posted this several times.
[iu]n your personal vendetta against the CEO,the kind which often come from previous employees, you know the things u have said are false bc I've posted the ff info before and it is readily available to everybody on the NNLX website and otc markets
[/u]
last NNLX financials CEO had loaned NNLX $100,958. In fact, back then bashers were making fun of him not being able to finish his house -not mentioning it was bc he had loaned NNLX over 100k, bc bashers are not interested in the truth.
NNLX current assets(CA) 122k current liabilites (CL) 115k of which 100k was loan from CEO
most pinks dont have products or revenues. For those who do, many have a highly negative current ratio,meaning current liabilities exceed current assets. Many pinks are defacto bankrupt. NNLX has avoided that by very carefully watching and cutting costs,avoiding toxic financing,while increasing revenues.
Even Walmart has had CL's exceeding CA's last 2 years w 59.664 CA and 78.521B CL's! so WMT's CL's exceed CA's by 18.857B!!! yet nobody is crying Walmart is falling
Financial Matters
As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market.
The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors.
The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised.
To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors
--- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.
In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.
Oct 26, 2015:
NanoLogix BioTechnology announces:
1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. The research was on three bacteria --- Neisseria Gonorrhea, Group B Streptococcus, and Enterococcus and was focused upon their rapid detection, identification, and the determination of their antibiotic resistance and sensitivity to multiple antibiotics. The results, in a few words, are: very positive, huge, phenomenal, great, unprecedented , to say the least. The N-Assay appears to work rapidly to identify any bacteria for which there exists an antibody.
2) With the delivery today of 100,000+ petri plates, NanoLogix Biotechnology has moved exclusively to using petri plates from Gosselin (A Corning company). The Gosselin products, previously purchased by the Company in 50,000+ plate lots, have enabled the company to increase economy of scale by 20% over other manufacturers' products
3) NanoLogix has reached an agreement with a multi-billion dollar medical technology company to customize the N-Assay diagnostic technology for their requirements. The work is being financed by the client and upon successful completion is projected to result in sales of multiple thousands of N-Assay kits.
4) The largest single-customer, single-day sale in the history of the company has just occurred , for an amount in excess of $30,000.00 The order was for agar-filled petri plates.
April 19,2018
Update On Petri FlatPack International Patent Status
Pursuant to NanoLogix' International Patent Offering
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
Posted On: 04/12/2018 12:44:04 PM
Posted By: Kachingpdx1
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
International Patent Offering
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
?The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Feb 24, 2014:
NanoLogix Petri technology sets new record for shelf life, NanoLogix has been informed by an independent third-party* testing facility that the ongoing room temperature shelf life test results from 7 Feb 2014 have successfully reached the 19-month point with NanoLogix Tryptic Soy Agar (TSA) plates packed in FlatPacks in July 2012 performing as well as one-week old competitor's plates.
In this ongoing study, NanoLogix TSA petri plate shelf life has reached nearly 10 times the competition's room temperature shelf life of slightly over 2 months. Prior to this study, the standard for storage of TSA petri plates was for cold storage only, for a period of 3-1/2 months. In internal company cold storage tests, NanoLogix plates are approaching the three-year point with no loss of viability. The importance of these results cannot be overstated --- growth media and petri plates have historically been mixed and filled (or poured) in locations that are limited to the states, regions, or countries in which the users are located due to the perishable nature of the products. The long shelf life of our products, and resistance to breakage in shipment of NanoLogix products are producing a paradigm shift on the part of those who are the product end users to one where they can now take delivery of our products thousands of miles distant from the production location and be assured that they have a product that significantly outlasts others made onsite or locally. A number of our petri-based products can be stored at room temperature for months or more, a feature that is unique to NanoLogix products and one that reduces energy requirements significantly on projects both large and small, with no need for cold storage equipment for our TSA (19+ months), Nematode Growth Media (12+ months), Chocolate Agar (10+ months) petri plates.
*NanoLogix is prohibited by contract from revealing the identity of the main third-party entity with which they work. more >>>
(3)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼